Search Results - "Mensa, Federico J"

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment by Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.

“…Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response,…”
Get full text

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older by Foster, Graham R, Asselah, Tarik, Kopecky-Bromberg, Sarah, Lei, Yang, Asatryan, Armen, Trinh, Roger, Zadeikis, Neddie, Mensa, Federico J

“…Finding safe and effective treatments for chronic hepatitis C virus (HCV) infection in the elderly is of clinical interest given the comorbidities and…”
Get full text

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection by Wyles, David, Weiland, Ola, Yao, Betty, Weilert, Frank, Dufour, Jean-Francois, Gordon, Stuart C., Stoehr, Albrecht, Brown, Ashley, Mauss, Stefan, Zhang, Zhenzhen, Pilot-Matias, Tami, Rodrigues, Lino, Mensa, Federico J, Poordad, Fred

Get full text

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data by van den Ouweland, Frank, Charpentier, Nicola, Türeci, Özlem, Rizzi, Ruben, Mensa, Federico J, Lindemann, Claudia, Pather, Shanti

“…The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and…”
Get full text

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials by Brown, Ashley, Welzel, Tania M., Conway, Brian, Negro, Francesco, Bräu, Norbert, Grebely, Jason, Puoti, Massimo, Aghemo, Alessio, Kleine, Henning, Pugatch, David, Mensa, Federico J., Chen, Yaozhu J., Lei, Yang, Lawitz, Eric, Asselah, Tarik

“…Background & Aims Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non‐adherence can…”
Get full text

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection by Naganuma, Atsushi, Chayama, Kazuaki, Notsumata, Kazuo, Gane, Edward, Foster, Graham R., Wyles, David, Kwo, Paul, Crown, Eric, Bhagat, Abhi, Mensa, Federico J., Otani, Tetsuya, Larsen, Lois, Burroughs, Margaret, Kumada, Hiromitsu

“…Background Chronic hepatitis C virus (HCV) infection with genotypes (GT) 1 and 2 accounts for over 50% of HCV infections globally, including over 97% of all…”
Get full text

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir by Berger, Kristi L, Sarrazin, Christoph, Nelson, David R, Scherer, Joseph, Sha, Nanshi, Marquis, Martin, Côté-Martin, Alexandra, Vinisko, Richard, Stern, Jerry O, Mensa, Federico J, Kukolj, George

“…The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and…”
Get full text

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination by Albertson, Timothy E., Hansen, Caitlin, Bihari, Smiti, Gayed, Juleen, Xu, Xia, Simón-Campos, J. Abraham, Dever, Michael E., Cardona, Jose F., Mitha, Essack, Baker, Jeffrey B., Keep, Georgina, Oladipupo, Islamiat, Mensa, Federico J., Feng, Ye, Ma, Hua, Koury, Kenneth, Mather, Susan, Ianos, Claudia Ana, Anderson, Annaliesa S., Türeci, Özlem, Şahin, Uǧur, Gruber, William C., Gurtman, Alejandra, Sabharwal, Charu, Kitchin, Nicholas

“…Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin…”
Get full text

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection by Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W, Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K, Gane, Edward J, Stern, Jerry O, Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O, Mensa, Federico J

“…Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is…”
Get full text

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment by Gane, Edward, Lawitz, Eric, Pugatch, David, Papatheodoridis, Georgios, Bräu, Norbert, Brown, Ashley, Pol, Stanislas, Leroy, Vincent, Persico, Marcello, Moreno, Christophe, Colombo, Massimo, Yoshida, Eric M, Nelson, David R, Collins, Christine, Lei, Yang, Kosloski, Matthew, Mensa, Federico J

“…In this uncontrolled trial involving 104 patients with hepatitis C virus infection and stage 4 or 5 kidney disease, treatment with glecaprevir and pibrentasvir…”
Get full text

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial by Forns, Xavier, Lee, Samuel S, Valdes, Joaquin, Lens, Sabela, Ghalib, Reem, Aguilar, Humberto, Felizarta, Franco, Hassanein, Tarek, Hinrichsen, Holger, Rincon, Diego, Morillas, Rosa, Zeuzem, Stefan, Horsmans, Yves, Nelson, David R, Yu, Yao, Krishnan, Preethi, Lin, Chih-Wei, Kort, Jens J, Mensa, Federico J

“…The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained…”
Get full text

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis by Asselah, Tarik, Kowdley, Kris V., Zadeikis, Neddie, Wang, Stanley, Hassanein, Tarek, Horsmans, Yves, Colombo, Massimo, Calinas, Filipe, Aguilar, Humberto, de Ledinghen, Victor, Mantry, Parvez S., Hezode, Christophe, Marinho, Rui Tato, Agarwal, Kosh, Nevens, Frederik, Elkhashab, Magdy, Kort, Jens, Liu, Ran, Ng, Teresa I., Krishnan, Preethi, Lin, Chih-Wei, Mensa, Federico J.

“…Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment…”
Get full text

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial by Brown, Robert S., Buti, Maria, Rodrigues, Lino, Chulanov, Vladimir, Chuang, Wan-Long, Aguilar, Humberto, Horváth, Gábor, Zuckerman, Elimelech, Carrion, Barbara Rosado, Rodriguez-Perez, Federico, Urbánek, Petr, Abergel, Armand, Cohen, Eric, Lovell, Sandra S., Schnell, Gretja, Lin, Chih-Wei, Zha, Jiuhong, Wang, Stanley, Trinh, Roger, Mensa, Federico J., Burroughs, Margaret, Felizarta, Franco

“…[Display omitted] •343 treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis.•Glecaprevir/pibrentasvir for 8 weeks achieved 99.7%…”
Get full text

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis by Kwo, Paul Y, Poordad, Fred, Asatryan, Armen, Wang, Stanley, Wyles, David L, Hassanein, Tarek, Felizarta, Franco, Sulkowski, Mark S, Gane, Edward, Maliakkal, Benedict, Scott Overcash, J, Gordon, Stuart C, Muir, Andrew J, Aguilar, Humberto, Agarwal, Kosh, Dore, Gregory J, Lin, Chih-Wei, Liu, Ran, Lovell, Sandra S, Ng, Teresa I, Kort, Jens, Mensa, Federico J

“…Graphical abstract…”
Get full text

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis by Puoti, Massimo, Foster, Graham R., Wang, Stanley, Mutimer, David, Gane, Edward, Moreno, Christophe, Chang, Ting Tsung, Lee, Samuel S., Marinho, Rui, Dufour, Jean-Francois, Pol, Stanislas, Hezode, Christophe, Gordon, Stuart C., Strasser, Simone I., Thuluvath, Paul J., Zhang, Zhenzhen, Lovell, Sandra, Pilot-Matias, Tami, Mensa, Federico J.

“…[Display omitted] •A short-duration, pangenotypic cure for HCV infection may help treat more patients.•Glecaprevir plus pibrentasvir (G/P) therapy for 8 weeks…”
Get full text

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection by Zeuzem, Stefan, Foster, Graham R, Wang, Stanley, Asatryan, Armen, Gane, Edward, Feld, Jordan J, Asselah, Tarik, Bourlière, Marc, Ruane, Peter J, Wedemeyer, Heiner, Pol, Stanislas, Flisiak, Robert, Poordad, Fred, Chuang, Wan-Long, Stedman, Catherine A, Flamm, Steven, Kwo, Paul, Dore, Gregory J, Sepulveda-Arzola, Gladys, Roberts, Stuart K, Soto-Malave, Ruth, Kaita, Kelly, Puoti, Massimo, Vierling, John, Tam, Edward, Vargas, Hugo E, Bruck, Rafi, Fuster, Francisco, Paik, Seung-Woon, Felizarta, Franco, Kort, Jens, Fu, Bo, Liu, Ran, Ng, Teresa I, Pilot-Matias, Tami, Lin, Chih-Wei, Trinh, Roger, Mensa, Federico J

“…In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained…”
Get full text

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial by Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.

“…This study assessed the efficacy and safety of ribavirin‐free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3…”
Get full text

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure by Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.

“…Patients with hepatitis C virus (HCV) who have virological failure (VF) after treatment containing a nonstructural protein 5A (NS5A) inhibitor have limited…”
Get full text

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials by Krishnan, Preethi, Pilot-Matias, Tami, Schnell, Gretja, Tripathi, Rakesh, Ng, Teresa I, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Mensa, Federico J, Collins, Christine

“…Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to…”
Get full text

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years by Winokur, Patricia, Gayed, Juleen, Fitz-Patrick, David, Thomas, Stephen J., Diya, Oyeniyi, Lockhart, Stephen, Xu, Xia, Zhang, Ying, Bangad, Vishva, Schwartz, Howard I., Denham, Douglas, Cardona, Jose F., Usdan, Lisa, Ginis, John, Mensa, Federico J., Zou, Jing, Xie, Xuping, Shi, Pei-Yong, Lu, Claire, Buitrago, Sandra, Scully, Ingrid L., Cooper, David, Koury, Kenneth, Jansen, Kathrin U., Türeci, Özlem, Şahin, Uğur, Swanson, Kena A., Gruber, William C., Kitchin, Nicholas

“…The immunogenicity of a bivalent mRNA vaccine with both ancestral and omicron BA.1 sequences elicited higher neutralization titers against BA.1 than did the…”
Get full text